Get started
United Therapeutics CorporationUnited Therapeutics CorporationUnited Therapeutics Corporation

United Therapeutics Corporation

No trades
See on Supercharts
Overview
Financials News Ideas Discussions Technicals Forecast Seasonals

UTHR chart


Full chart

UTHR upcoming earnings

Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—

Key stats


Market capitalization
‪18.30 B‬ USD
Dividend yield (indicated)
—
Price to earnings Ratio (TTM)
17.68
Basic EPS (TTM)
24.34 USD
Net income (FY)
‪984.80 M‬ USD
Revenue (FY)
‪2.33 B‬ USD
Shares float
‪43.86 M‬
Beta (1Y)
0.26

Employees


Employees (FY)
‪1.17 K‬
Change (1Y)
+183 +18.58%
Revenue / Employee (1Y)
‪1.99 M‬ USD
Net income / Employee (1Y)
‪843.15 K‬ USD

About United Therapeutics Corporation


Sector
Health Technology
CEO
Martine A. Rothblatt
Headquarters
Silver Spring
Website
unither.com
Founded
1996
FIGI
BBG000BV4XJ1
United Therapeutics Corp. is a biotechnology company, which engages in the development and commercialization of products for patients with chronic and life-threatening conditions. Its products include Adcirca, Orenitram, Remodulin, TYVASO, and Unituxin. The company was founded by Martine A. Rothblatt on June 26, 1996 and is headquartered in Silver Spring, MD.

Financials


Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:—
‪0.00‬

UTHR news



Ideas



See all ideas 

Technicals

Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Analyst rating


An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Seasonals


Displays a symbol's price movements over previous years to identify recurring trends.

Sparks


Curated watchlists where UTHR is featured.

See all sparks 

Frequently Asked Questions


The current price of UTHR is 410.00 USD — it has increased by 1.85% in the past 24 hours. Watch United Therapeutics Corporation stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange United Therapeutics Corporation stocks are traded under the ticker UTHR.
UTHR stock has risen by 9.11% compared to the previous week, the month change is a 15.24% rise, over the last year United Therapeutics Corporation has showed a 81.08% increase.
We've gathered analysts' opinions on United Therapeutics Corporation future price: according to them, UTHR price has a max estimate of 600.00 USD and a min estimate of 302.00 USD. Watch UTHR chart and read a more detailed United Therapeutics Corporation stock forecast: see what analysts think of United Therapeutics Corporation and suggest that you do with its stocks.
UTHR reached its all-time high on Nov 1, 2024 with the price of 377.93 USD, and its all-time low was 4.28 USD and was reached on Dec 11, 2001. View more price dynamics on UTHR chart.
See other stocks reaching their highest and lowest prices.
UTHR stock is 3.78% volatile and has beta coefficient of 0.26. Track United Therapeutics Corporation stock price on the chart and check out the list of the most volatile stocks — is United Therapeutics Corporation there?
Today United Therapeutics Corporation has the market capitalization of ‪18.30 B‬, it has increased by 3.20% over the last week.
Yes, you can track United Therapeutics Corporation financials in yearly and quarterly reports right on TradingView.
United Therapeutics Corporation is going to release the next earnings report on Feb 19, 2025. Keep track of upcoming events with our Earnings Calendar.
UTHR earnings for the last quarter are 6.39 USD per share, whereas the estimation was 6.52 USD resulting in a −2.04% surprise. The estimated earnings for the next quarter are 6.59 USD per share. See more details about United Therapeutics Corporation earnings.
United Therapeutics Corporation revenue for the last quarter amounts to ‪748.90 M‬ USD, despite the estimated figure of ‪722.62 M‬ USD. In the next quarter, revenue is expected to reach ‪739.92 M‬ USD.
UTHR net income for the last quarter is ‪309.10 M‬ USD, while the quarter before that showed ‪278.10 M‬ USD of net income which accounts for 11.15% change. Track more United Therapeutics Corporation financial stats to get the full picture.
No, UTHR doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Nov 10, 2024, the company has ‪1.17 K‬ employees. See our rating of the largest employees — is United Therapeutics Corporation on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. United Therapeutics Corporation EBITDA is ‪1.35 B‬ USD, and current EBITDA margin is 53.35%. See more stats in United Therapeutics Corporation financial statements.
Like other stocks, UTHR shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade United Therapeutics Corporation stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So United Therapeutics Corporation technincal analysis shows the strong buy rating today, and its 1 week rating is strong buy. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating United Therapeutics Corporation stock shows the strong buy signal. See more of United Therapeutics Corporation technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.